Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): a systematic review

다국어 초록 (Multilingual Abstract)

Background: The World Health Organization characterized the Coronavirus disease 2019 (COVID-19) as a pandemic on March 11th. Many clinical trials on COVID-19 have been registered, and we aim to review the study characteristics and provide guidance for future trials to avoid duplicated effort.
Methods: Studies on COVID-19 registered before March 3rd, 2020 on eight registry platforms worldwide were searched and the data of design, participants, interventions, and outcomes were extracted and analyzed.
Results: Three hundred and ninety-three studies were identified and 380 (96.7%) were from mainland China, while 3 in Japan, 3 in France, 2 in the US, and 3 were international collaborative studies. Two hundred and sixty-six (67.7%) aimed at therapeutic effect, others were for prevention, diagnosis, prognosis, etc. Two hundred and two studies (51.4%) were randomized controlled trials. Two third of therapeutic studies tested Western medicines including antiviral drugs (17.7%), stem cell and cord blood therapy (10.2%), chloroquine and derivatives (8.3%), 16 (6.0%) on Chinese medicines, and 73 (27.4%) on integrated therapy of Western and Chinese medicines. Thirty-one studies among 266 therapeutic studies (11.7%) used mortality as primary outcome, while the most designed secondary outcomes were symptoms and signs (47.0%). Half of the studies (45.5%) had not started recruiting till March 3rd.
Conclusion: Inappropriate outcome setting, delayed recruitment and insufficient numbers of new cases in China implied many studies may fail to complete. Strategies and protocols of the studies with robust and rapid data sharing are warranted for emergency public health events, helping the timely evidence-based decision-making.

참고문헌 (Reference)

1 The State Council, "the People’s Republic of China Premier Li Keqiang presided over a meeting of the Central Leading Group for New Coronary Pneumonia Epidemic Situation, deployed further classification, effective prevention and control, required optimization of diagnosis and treatment, and accelerated scientific research on drug control"

2 Song Y, "XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia : a randomized controlled trial" 47 : e735-43, 2019

3 Lv SJ, "The protective effect of Shenfu injection against elderly severe pneumonia" 43 : 711-715, 2017

4 Wei X, "The global registry of COVID-19 clinical trials: indicating the design of traditional Chinese medicine clinical trials" 2020

5 Ministry of Science, "Technology of the People’s Republic of China. Letter of the joint prevention and control mechanism of the State Council on notice on standardizing medical institutions to carry out clinical research on new coronavirus pneumonia drug treatment"

6 Wang P, "Tanreqing injection for acute bronchitis disease : a systematic review and meta-analysis of randomized controlled trials" 25 : 143-158, 2016

7 Maxmen A, "Slew oftrials launch to test coronavirus treatments in China" 578 : 347-348, 2020

8 Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China" e20099-, 2020

9 National Health Commission of the People’s Republic of China, "Prevention and control of new coronavirus pneumonia"

10 Yao Y, "Potential material basis of Kangbingdu Keli for the treatment of coronavirus pneumonia 2019(COVID-19)based on network pharmacology and molecular docking technology" 51 : 1386-1396, 2020

11 Wang C, "Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial[published correction appears inAnn Intern Med. 2012 Jan 3;156(1 Pt 1):71]" 155 : 217-225, 2011

12 Cui J, "Origin and evolution of pathogenic coronaviruses" 17 : 181-192, 2019

13 World Health Organization, "Novel Coronavirus (2019-nCoV): strategic preparedness and response plan for the new coronavirus"

14 Li R, "Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARSCoV-2)" 104761-, 2020

15 Zhao R, "Intervening effect of promoting lung and resolving phlegm method on a mouse model combining disease and syndrome of human coronavirus pneumonia with cold-dampness pestilence attacking lung" 1-7, 2020

16 Zhou Z, "Honeysuckle-encoded atypical microRNA2911 directly targets influenza A viruses" 25 : 39-49, 2015

17 China Association of Acupuncture-Moxibustion, "Guidance on acupuncture intervention for COVID-19 by China Association of Acupuncture-Moxibustion"

18 World Health Organization, "Guidance for managing ethical issues in infectious disease outbreaks"

19 Liu X, "Guidance and suggestions on rehabilitation training of integrated traditional Chinese and western medicine for functional recovery of patients withnovel coronavirus pneumonia" 54 : 9-13, 2020

20 Wang Z, "Expert consensus statement on Xiyanping Injection for respiratory system infectious diseases in clinical practice(adults)" 44 : 5282-5286, 2019

21 World Health Organization, "Ethical issues related to study design for trials on therapeutics for Ebola virus disease"

22 Chang D, "Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China" 323 : 1092-1093, 2020

23 Liu Y, "Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza : results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial" 8 : 55176-55186, 2017

24 Jin J, "Effectiveness and safety of Ganke Shuangqing capsule for acute upper respiratory tract infection : a systematic review and meta-analysis" 15 : 24-29, 2020

25 Qun Li, "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia" Massachusetts Medical Society 382 (382): 1199-1207, 2020

26 Anthony S. Fauci, "Covid-19 — Navigating the Uncharted" Massachusetts Medical Society 382 (382): 1268-1269, 2020

27 Worldometer, "Coronavirus update (live)"

28 World Health Organization, "Coronavirus (COVID-19) events as they happen"

29 World Health Organization, "Consultation on clinical trial design for ebola virus disease"

30 Luo J, "Compound Danshen(Salvia miltiorrhiza)dripping pill for coronary heart disease : an overview of systematic reviews" 43 : 25-43, 2015

31 Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study" S0140-6736 (S0140-6736): 30566-3-, 2020

32 Wang D, "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China" e201585-, 2020

33 Luo H, "Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs [published online ahead of print, 2020 Feb 17]" 1-8, 2020

34 Tang Y, "Antiviral effects of Shuanghuanglian injection powder against influenza A virus H5N1 in vitro and in vivo" 121 : 318-324, 2018